<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756183</url>
  </required_header>
  <id_info>
    <org_study_id>SPECIAL</org_study_id>
    <nct_id>NCT01756183</nct_id>
  </id_info>
  <brief_title>Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer</brief_title>
  <official_title>Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients With Unresectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the
      Patients with Unresectable Gastric Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effectiveness and safety of S-1 + Paclitaxel for the peri-operative
      chemotherapy in Chinese patients with unresectable gastric cancer, so as to further find out
      the optimal protocol for the peri-operative chemotherapy in the patients with gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radical resection rate</measure>
    <time_frame>3 months</time_frame>
    <description>radical resection rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number and degree of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reaction rate</measure>
    <time_frame>2 months</time_frame>
    <description>the reaction rate of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival time</measure>
    <time_frame>3 years</time_frame>
    <description>the overall survival time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Surgically-Created Resection Cavity</condition>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>S-1 + Paclitaxel Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
Paclitaxel: 150 mg/m2, iv, 3h, at D1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 + Paclitaxel Chemotherapy</intervention_name>
    <description>Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1</description>
    <arm_group_label>S-1 + Paclitaxel Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Unresectable gastric cancer as proven histologically (AJCC, Version 7) under any following
        condition: Unable radical excision due to the local metastasis or invasion Metastasis to
        the lymph node beside the abdominal aorta Non-extensive metastasis to liver (not more than
        three metastatic foci of radical excision)

          -  Definitely diagnosed as above stage of stomach cancer before the operation via CT or
             MRI, ultrasonic endoscopy and blood tumor antigen test, or through the laparoscopy if
             necessary

          -  Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)

          -  ECOG (Eastern Cooperative Oncology Group) : 0~2

          -  Age: 18~75 years old

          -  Normal hemodynamic indices before the recruitment (including blood cell count and
             liver/kidney function). For example: WBC&gt;4.0×109/L, NEU &gt;1.5×109/L, PLT&gt;100×109/L,
             BIL&lt;1.5 times of upper limit of normal reference value, ALT and AST&lt;2.5 times of upper
             limit of normal reference value, and CRE&lt;1.2mg/dl

          -  Good cardiac function before the recruitment, no seizure of myocardial infarction in
             past half year, and controllable hypertension and other coronary heart diseases

          -  Not concomitant with other uncontrollable benign diseases before the recruitment (e.g.
             the infection in the lung, kidney and liver)

          -  Not participating in other study projects before and during the treatment

          -  Signed the Informed Consent Form

        Exclusion Criteria:

          -  Not conforming to above inclusion criteria

          -  Distal metastasis to lung, brain and bone (except the liver)

          -  Ever operation on the stomach

          -  Operation intolerance due to other systemic basic diseases

          -  Ever administered other drugs (including TCM drugs) before the recruitment, or no
             guarantee of progress according to the study requirement after the recruitment

          -  Allergy to the drugs in this protocol

          -  Pregnant or lactating women

          -  Women at childbearing age and of pregnancy desire during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiangdong Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiangdong Cheng, MD</last_name>
    <phone>+86 571 88122516</phone>
    <email>abdsurg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiangdong Cheng, MD</last_name>
      <phone>+86 571 88122516</phone>
      <email>abdsurg@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>xiangdong Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2012</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

